Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Sato, Eisai to Wind Up Collab on Antifungal Nailin
March 5, 2025
- Nippon Kayaku Files Nuvation-Partnered ROS1 Inhibitor in Japan
March 5, 2025
- Enhertu Hits OS Goal in 2nd-Line Gastric Cancer Use
March 5, 2025
- Japan Pharma Market Hits 11.5 Trillion Yen in 2024, Keytruda Wins Crown: IQVIA
March 5, 2025
- 680 Employees Exit Takeda in Buyout Program, 10%-Plus of Japan Staff
March 4, 2025
- Novartis Bags Global Rights to Kyorin’s MRGPRX2 Antagonist
March 4, 2025
- Australia Rejects Lecanemab Again, Eisai to Challenge Decision
March 4, 2025
- Blackstone to Buy 60% Stake in Japan CRO CMIC
March 4, 2025
- Alfresa to Build New Cell Therapy CDMO Site in Japan
March 4, 2025
- ASKA Ties Up with Philippines’ MedChoice in Thyroid Space
March 4, 2025
- Japan’s 1st CGP Assay for Blood Cancer Now Available: Otsuka
March 4, 2025
- Enhertu Gets EMA Backing for HER2-Low/Ultralow Breast Cancer
March 4, 2025
- Nxera Assigns Cenerimod Rights in Japan, APAC to Viatris
March 3, 2025
- Ono to Consolidate US, European Operations to Deciphera
March 3, 2025
- Over 60% of Doctors Have Prejudices about Obesity: Lilly/Mitsubishi Survey
March 3, 2025
- GSK Vows to Ensure Proper Use of Shingles Jab towards NIP Inclusion
March 3, 2025
- Eisai Licenses Tasfygo to SciClone in Greater China Region
March 3, 2025
- Chiome Inks Research Collab Pact with OmniAb
March 3, 2025
- Cariprazine Broadens Label in Thailand: Mitsubishi Tanabe
March 3, 2025
- 2-Dose Vial of COVID Vaccine Filed in Japan: Meiji
March 3, 2025
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…